Marker for predicting treatment response to anti-cancer agent in solid cancer patients
OwnerJaeyoung KIM, Jingmin CHE +4inventors
InventorsJaeyoung KIM, Jingmin CHE, Hyun Cheol CHUNG, Sun Young RHA, Woo Sun KWON, Tae Soo KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a marker for predicting a responsiveness of a solid cancer patient to an anticancer agent. The marker according to the present invention can be advantageously used to select a subgroup, who effectively responds to an anticancer therapy with a specific anticancer agent, from among solid cancer patients, or to determine a therapy method for treatment of solid cancer patients.
Claims19
A method for providing information for predicting responsiveness of a solid cancer patient to an anticancer agent, the method comprising detecting in a sample the presence or absence of an SNP (NCBI refSNP ID:
- rs3730089) at nucleotide position 21 in the nucleotide sequence of SEQ ID NO:
- 1, which is a portion of a PIK3R1 gene.
A primer composition for predicting responsiveness of a solid cancer patient to an anticancer agent, the primer composition comprising a primer for detecting a polynucleotide comprising 10 or more consecutive nucleotides including the 21st nucleotide in the nucleotide sequence of SEQ ID NO:
- 1, which is a portion of a PIK3R1 gene, or a complementary polynucleotide thereof.
A probe composition for predicting responsiveness of a solid cancer patient to an anticancer agent, the probe composition comprising a probe for hybridizing specifically to a polynucleotide comprising 10 or more consecutive nucleotides including the 21st nucleotide in the nucleotide sequence of SEQ ID NO:
- 1, which is a portion of a PIK3R1 gene, or a complementary polynucleotide thereof.
A method for screening a patient-specific therapeutic agent for treatment of solid cancer, the method comprising the step of:
- (a) detecting in a sample the presence or absence of an SNP (NCBI refSNP ID:
- rs3730089) at nucleotide position 21 in the nucleotide sequence of SEQ ID NO:
- 1, which is a portion of a PIK3R1 gene;
- and
- (b) when the SNP is present, selecting a phosphoinositide 3-kinase β (PI3Kβ) inhibitor as the patient-specific therapeutic agent.
Dependencies are inferred from the claim text.